Immunotech Laboratories Net Income
| IMMB Stock | USD 0.0002 0.0001 100.00% |
As of the 21st of February, Immunotech Laboratories retains the Risk Adjusted Performance of 0.1032, market risk adjusted performance of (0.91), and Standard Deviation of 12.31. Immunotech Laboratories technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Immunotech Laboratories' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immunotech Laboratories' valuation are provided below:We have found sixty available fundamental trends for Immunotech Laboratories, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immunotech Laboratories regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 54.1 K. The current year's Enterprise Value is expected to grow to about 2.3 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. As of February 21, 2026, Net Loss is expected to decline to -0.0008. In addition to that, Net Income Per E B T is expected to decline to 1.10. Immunotech | Net Income | Build AI portfolio with Immunotech Stock |
Immunotech Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunotech Laboratories is extremely important. It helps to project a fair market value of Immunotech Stock properly, considering its historical fundamentals such as Net Income. Since Immunotech Laboratories' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunotech Laboratories' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunotech Laboratories' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunotech Laboratories. Market participants price Immunotech higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Immunotech Laboratories assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.59) |
Immunotech Laboratories's market price often diverges from its book value, the accounting figure shown on Immunotech's balance sheet. Smart investors calculate Immunotech Laboratories' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Immunotech Laboratories' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immunotech Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunotech Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunotech Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immunotech Laboratories 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immunotech Laboratories' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immunotech Laboratories.
| 11/23/2025 |
| 02/21/2026 |
If you would invest 0.00 in Immunotech Laboratories on November 23, 2025 and sell it all today you would earn a total of 0.00 from holding Immunotech Laboratories or generate 0.0% return on investment in Immunotech Laboratories over 90 days. Immunotech Laboratories is related to or competes with Rocket Pharmaceuticals, Aura Biosciences, Annexon, Solid Biosciences, Larimar Therapeutics, Altimmune, and Autolus Therapeutics. Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficienc... More
Immunotech Laboratories Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immunotech Laboratories' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immunotech Laboratories upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1166 |
Immunotech Laboratories Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunotech Laboratories' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immunotech Laboratories' standard deviation. In reality, there are many statistical measures that can use Immunotech Laboratories historical prices to predict the future Immunotech Laboratories' volatility.| Risk Adjusted Performance | 0.1032 | |||
| Jensen Alpha | 1.62 | |||
| Total Risk Alpha | 0.3667 | |||
| Treynor Ratio | (0.92) |
Immunotech Laboratories February 21, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1032 | |||
| Market Risk Adjusted Performance | (0.91) | |||
| Mean Deviation | 2.98 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 12.31 | |||
| Variance | 151.52 | |||
| Information Ratio | 0.1166 | |||
| Jensen Alpha | 1.62 | |||
| Total Risk Alpha | 0.3667 | |||
| Treynor Ratio | (0.92) | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
Immunotech Laboratories Backtested Returns
Immunotech Laboratories is out of control given 3 months investment horizon. Immunotech Laboratories holds Efficiency (Sharpe) Ratio of 0.13, which attests that the entity had a 0.13 % return per unit of risk over the last 3 months. We have collected data for eighteen different technical indicators, which can help you to evaluate if expected returns of 1.59% are justified by taking the suggested risk. Use Immunotech Laboratories Risk Adjusted Performance of 0.1032, market risk adjusted performance of (0.91), and Standard Deviation of 12.31 to evaluate company specific risk that cannot be diversified away. Immunotech Laboratories holds a performance score of 10 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -1.64, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Immunotech Laboratories are expected to decrease by larger amounts. On the other hand, during market turmoil, Immunotech Laboratories is expected to outperform it. Use Immunotech Laboratories skewness, as well as the relationship between the rate of daily change and price action indicator , to analyze future returns on Immunotech Laboratories.
Auto-correlation | 0.00 |
No correlation between past and present
Immunotech Laboratories has no correlation between past and present. Overlapping area represents the amount of predictability between Immunotech Laboratories time series from 23rd of November 2025 to 7th of January 2026 and 7th of January 2026 to 21st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immunotech Laboratories price movement. The serial correlation of 0.0 indicates that just 0.0% of current Immunotech Laboratories price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Immunotech Net Income Per Share
Net Income Per Share |
|
Based on the recorded statements, Immunotech Laboratories reported net income of (977,570). This is 100.29% lower than that of the Healthcare sector and 101.4% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.17% higher than that of the company.
Immunotech Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunotech Laboratories' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunotech Laboratories could also be used in its relative valuation, which is a method of valuing Immunotech Laboratories by comparing valuation metrics of similar companies.Immunotech Laboratories is currently under evaluation in net income category among its peers.
Immunotech Fundamentals
| Current Valuation | 1.25 M | ||||
| Shares Outstanding | 550.66 K | ||||
| Price To Book | 0.01 X | ||||
| EBITDA | (944.59 K) | ||||
| Net Income | (977.57 K) | ||||
| Book Value Per Share | 0.11 X | ||||
| Earnings Per Share | (0.59) X | ||||
| Beta | -125.21 | ||||
| Market Capitalization | 55 | ||||
| Total Asset | 10.56 M | ||||
| Retained Earnings | (2.85 M) | ||||
| Working Capital | (2.32 M) | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 3.04 M |
About Immunotech Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunotech Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunotech Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunotech Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunotech Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunotech Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunotech Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunotech Laboratories Stock:Check out For information on how to trade Immunotech Stock refer to our How to Trade Immunotech Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunotech Laboratories. Market participants price Immunotech higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Immunotech Laboratories assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.59) |
Immunotech Laboratories's market price often diverges from its book value, the accounting figure shown on Immunotech's balance sheet. Smart investors calculate Immunotech Laboratories' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Immunotech Laboratories' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immunotech Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunotech Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunotech Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.